Refine Search

Search Results -

Terms	Documents
dendritic near cryopreserv\$	3

US Pre-Grant Publication Full-Text Database

US Patents Full-Text Database

Database:

US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins

Search:

L5 Refine Search







Search History

DATE: Thursday, October 04, 2007 Purge Queries Printable Copy Create Case

256

L1

Set Name Query Hit Count Set Name side by side result set DB=USPT; PLUR=YES; OP=OR dendritic near cryopreserv\$ L5 3 <u>L5</u> L4 L3 and L2 62 <u>L4</u> L3 matur\$ or activated 555093 L3 L2 L1 and @py<2002 L2 74

dendritic and cryopreserv\$

END OF SEARCH HISTORY

L1

Hit List

First Hit Clear Generate Collection Print Fwd Refs Bkwd Refs

Generate OACS

Search Results - Record(s) 1 through 3 of 3 returned.

1. Document ID: US 7198948 B2

L5: Entry 1 of 3

File: USPT

Apr 3, 2007

US-PAT-NO: 7198948

DOCUMENT-IDENTIFIER: US 7198948 B2

TITLE: Methods and compositions for obtaining mature dendritic cells

DATE-ISSUED: April 3, 2007

PRIOR-PUBLICATION:

DOC-ID

DATE

US 20020160430 A1

October 31, 2002

INVENTOR-INFORMATION:

NAME CITY ZIP CODE STATE COUNTRY Steinman; Ralph M. Westport CT US Bhardwaj; Nina Montclair NJ US Schuler; Gerold Spardorf DE

US-CL-CURRENT: 435/377; 435/385, 435/386

ABSTRACT:

We describe an improved method for generating sizable numbers of mature dendritic cells from nonproliferating progenitors in human blood. The first step or "priming" phase is a culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4 to produce immature dendritic cells. The second step or "differentiation" phase requires the exposure to dendritic cell maturation factor such as monocyte conditioned medium. Using this two-step approach, substantial yields are obtained. The dendritic cells derive from this method have all the features of mature cells. They include a stellate cell shape, nonadherence to plastic, and very strong T cell stimulatory activity. The mature dendritic cells produced according to this invention are useful for activating T cells.

9 Claims, 14 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 14

Full Title Citation Front Review Classification Date Reference Sequences Figure (18) Claims KMC Draw.	Full	Titl∈	Citation	Front	Review	Classification	Date	Reference	Sequences	Alies (metro)	Claims	KWIC	Draw, D
---	------	-------	----------	-------	--------	----------------	------	-----------	-----------	---------------	--------	------	---------

☑ 2. Document ID: US 6274378 B1

L5: Entry 2 of 3 File: USPT Aug 14, 2001

US-PAT-NO: 6274378

DOCUMENT-IDENTIFIER: US 6274378 B1

TITLE: Methods and compositions for obtaining mature dendritic cells

DATE-ISSUED: August 14, 2001

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Steinman; Ralph M. Westport CT Bhardwaj; Nina Montclair NJ

Schuler; Gerold Spardorf DE

US-CL-CURRENT: 435/377; 435/325, 435/366, 435/375

ABSTRACT:

We describe an improved method for generating sizable numbers of mature dendritic cells from nonproliferating progenitors in human blood. The first step or "priming" phase is a culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4 to produce immature dendritic cells. The second step or "differentiation" phase requires the exposure to dendritic cell maturation factor such as monocyte conditioned medium. Using this two-step approach, substantial yields are obtained. The dendritic cells derive from this method have all the features of mature cells. They include a stellate cell shape, nonadherence to plastic, and very strong T cell stimulatory activity. The mature dendritic cells produced according to this invention are useful for activating T cells.

21 Claims, 31 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 19

Full Ti	tle Cit	ation F	ront	Review	Classification	Date	Reference	Claims	KAMC	Draw, De

☐ 3. Document ID: US 5788963 A

L5: Entry 3 of 3 File: USPT Aug 4, 1998

US-PAT-NO: 5788963

DOCUMENT-IDENTIFIER: US 5788963 A

TITLE: Isolation and/or preservation of dendritic cells for prostate cancer

immunotherapy

DATE-ISSUED: August 4, 1998

INVENTOR-INFORMATION:

NAME CITY STATE ZIP CODE COUNTRY

Murphy; Gerald P. Seattle WA
Boynton; Alton L. Redmond WA
Tjoa; Benjamin A. Seattle WA

US-CL-CURRENT: <u>424/93.21</u>; <u>424/185.1</u>, <u>424/277.1</u>

ABSTRACT:

Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic prostate cancer are disclosed. In one embodiment, human dendritic cells, after exposure to a prostate cancer antigen or specific antigenic peptide, are administered to a prostate cancer patient to activate the relevant T cell responses in vivo. In an alternate embodiment, human dendritic cells are exposed to a prostate cancer antigen or specific antigenic peptide in vitro and incubated or cultured with primed or unprimed T cells to activate the relevant T cell responses in vitro. The activated T cells are then administered to a prostate cancer patient. Methods and compositions for human dendritic cells with extended life span and cryopreserved dendritic cells are disclosed.

8 Claims, 9 Drawing figures Exemplary Claim Number: 1 Number of Drawing Sheets: 9

ıll Title Citation	Front	Review	Classification	Date	Reference		103	A TOTAL	表为[Claims	KMAC	
				mm 4 construction								
	Sent programme in the contract of					SECTION CONTRACTOR	200	TO SEC. AND	3 33 2 2 3 3		Se Se Ar	Traine,
ear Gene	erate Colle	ection	Print	F	wd Refs	(3) (3) E	Bkwd	Refs		Gener	ate O	4C
ear J Gene	erate Colle	ection	Print]	wd Refs	[3] [4] E	Bkwd(Refs		Gener	ate O	AC
Terms	erate Colle	ection	Print	<u> </u> F	wd Refs)			Refs Docum			ate O	AC

Display Format: REV Change Format

<u>Previous Page</u> <u>Next Page</u> <u>Go to Doc#</u>

14253603 Genuine Article#: 953LK Number of References: 34
Title; Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma (ABSTRACT AVAILABLE)
Author(s): Perabo FGE (REPRINT); Willert PL; Wirger A; Schmidt DH; von

Ruecker A; Mueller SC

Corporate Source: POB 1906/D-82309 Starnberg//Germany/ (REPRINT); Univ Bonn, Dept Urol, D-53105 Bonn//Germany/; Med Univ Lubeck, Dept Urol, Lubeck//Germany/; Univ Bonn, Inst Pathol, D-53105 Bonn//Germany/(perabo@lycos.com)

Journal: ANTICANCER RESEARCH, 2005, V25, N5 (SEP-OCT), P3565-3573

ISSN: 0250-7005 Publication date: 20050900

Publisher: INT INST ANTICANCER RESEARCH, EDITORIAL OFFICE 1ST KM
KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE

Language: English Document Type: ARTICLE

Abstract: Background: Superantigens are among the most potent T-cell mitogens known. Since T-cell activation and T-cell-derived cytokines play a role in the immune response associated with intravesical Bacillus Calmette-Guerin (BCG) application, this study was initiated to explore the fundamental aspects of a potential new immunomodulatory therapy for superficial bladder cancer. Since Superantigen-induced cytotoxicity is mediated by apoptosis, the effects of SEB (staphylococcal enterotoxin B)-Superantigen-activated PBMC (peripheral blood mononuclear cells) on bladder cancer cells were evaluated with regard to Fas/Fas-ligand-based interactions. Materials and Methods: Whether SEB can induce Fas-ligand expression on PBMC and the extent of cytokine secretion were examined by flow cytometry and specific ELISA. In addition, whether the SEB-activated PBMC are able to induce apoptosis in transitional cell carcinoma cells (TCC) was evaluated in co-culture experiments. Results: It was shown that SEB induced pronounced time- but not dose-dependent specific Fas-ligand expression on PBMC, lasting 1 h to 7 It after initiation of the experiment. Cleaved soluble Fas-ligand was detected in the culture supernatants 24 h after stimulation, but not earlier. Further, a strong time-dependent secretion of cytokines IL-2, IFN-gamma and TNF-alpha released from the SEB-stimulated PBMC was shown. In co-culture experiments, it was demonstrated that SEB-activated PBMC significantly induced apoptosis in TCC cells. The released cytokines from SEB-treated PBMC demonstrated only a minor, not significant, apoptotic response in TCC cells. Conclusion: This first evaluation of the possible mode of action of a Superantigen opens the door for extended studies of this interesting approach to the treatment of bladder cancer.

... Abstract: derived cytokines play a role in the immune response associated with intravesical Bacillus Calmette-Guerin (BCG) application, this study was initiated to explore the fundamental aspects of a potential new immunomodulatory...

...Identifiers--CALMETTE-GUERIN IMMUNOTHERAPY; HUMAN COLON-CARCINOMA; HUMAN T-CELLS; FAS-LIGAND; BLADDER-CANCER; ENTEROTOXIN-B; BACTERIAL SUPERANTIGEN; LYMPHOCYTES; DEATH; CYTOTOXICITY

4/3,K,AB/5 (Item 2 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2007 The Thomson Corp. All rts. reserv.

06069761 Genuine Article#: XT366 Number of References: 16
Title: An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease (ABSTRACT AVAILABLE)

Author(s): Kuniyuki S (REPRINT) ; Asada M

Corporate Source: JUSO MUNICIPAL HOSP, DIV DERMATOL, YODOGAWA KU, DEPT DERMATOL, JUSO HIGASHI 2-3-7/OSAKA 532//JAPAN/ (REPRINT); OSAKA CITY UNIV, SCH MED, DEPT PEDIAT/OSAKA 545//JAPAN/

Journal: JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, V37, N2,2,S (AUG), P303-304

ISSN: 0190-9622 Publication date: 19970800

Publisher: 'MOSBY-YEAR BOOK INC, 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO

63146-3318

Language: English Document Type: ARTICLE
Abstract: We describe a bacillus Calmette-Guerin (BCG) granuloma that
occurred during the course of Kawasaki disease. A 12-month-old male

```
Set
        Items
                 Description
                 BACTERIA? (2N) SUPERANTIGEN??
S1
         3467
S2
        37897
S3
             8
                 S1 AND S2
S4
             5
                 RD (unique items)
                 (IL(W)12) OR (INTERLEUKIN(W)12)
S5
        44569
S6
          777
                 S2 AND S5
S7
       159455
                 DENDRITIC
S8
          138
                 S6 AND S7
S9
           82
                 RD (unique items)
S10
           27
                 S9 AND PY<=2002
? s dendritic (5n)((IL(W)12) OR (INTERLEUKIN(W)12))
          159455 DENDRITIC
          446856 IL
         2273898 12
           36710 IL(W)12
          520274 INTERLEUKIN
         2273898 12
           30240 INTERLEUKIN(W)12
            1775 DENDRITIC (5N)((IL(W)12) OR (INTERLEUKIN(W)12))
     S11
? s s10 and s11
               27 S10
             1775 S11
              6 S10 AND S11
     S12
? t s12/3, k, ab/1-6
 12/3, K, AB/1
                  (Item 1 from file: 155)
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2007 Dialog. All rts. reserv.
13687414
           PMID: 11920565
    Autocrine
                IL-10 impairs dendritic cell (DC)-derived immune
responses to mycobacterial infection by suppressing DC trafficking to
draining lymph nodes and local ***IL*** - ***12***
                                                           production.
  Demangel Caroline; Bertolino Patrick; Britton Warwick J
  Centenary Institute of Cancer Medicine and Cell Biology, Newtown, NSW,
Australia.
             journal of immunology (Germany)
  European
                                                   Apr 2002, 32
                                                                      (4)
 p994-1002, ISSN 0014-2980--Print Journal Code: 1273201
  Publishing Model Print
  Document type: Comparative Study; Journal Article; Research Support,
Non-U.S. Gov't
  Languages: ENGLISH
  Main Citation Owner: NLM
  Record type: MEDLINE; Completed
  The production of IL-12 by dendritic cells (DC) early
in an immune response is considered critical for the polarization of CD4(+)
T lymphocyte response towards a Thl pattern, a key process in the clearance of intracellular pathogens. Infection of bone marrow-derived DC with
Mycobacterium
                bovis Bacillus Calmette Guerin (BCG) induced a
concurrent and dose-dependent releaseof IL-10 and
                                                        ***IL*** - ***12***
                                                                                 Here
   examined whether the production of IL-10 by DC affected their IL-
12
     response to mycobacterial infection and the generation of
protective immune responses in vivo. Compared to wild-type (WT) DC, DC
deficient for IL-10 synthesis (IL-10(-/-)) showed increased IL-12 production in response to BCG infection and CD40 stimuli in
vitro. Moreover, when transferred into mice, infected IL-10(-/-) DC were
more efficient than WT DC at inducing IFN-gamma production to mycobacterial
antigens in the draining lymph nodes (DLN). This effect was associated with
increased trafficking of \overline{\text{IL}}-10\,(\text{-/-}) DC to the DLN and enhanced \overline{\text{IL}}-10\,(\text{-/-})
  ***12***
              production by DC within the DLN. These data show that autocrine
IL-10 exerts a dual inhibitory effect on the induction of primary immune
responses by DC: first, by down-regulating the migration of infected DC to
```

the DLN and second, by modulating the IL-12 production by DC in the DLN. $\dot{\ }$

Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local ***IL*** - ***12*** production.

... ***2002*** ,

The production of IL-12 by dendritic cells (DC) early
in an immune response is considered critical for the polarization of CD4...
... of intracellular pathogens. Infection of bone marrow-derived DC with